Biotech | July 08, 2025
Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Women Health Card was launched exclusively for women health workers of the Tiruchirappalli City Corporation
_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Subscribe To Our Newsletter & Stay Updated
